Israeli company, IOptima Ltd, announced that it has obtained European Union CE Mark certification to sell its laser treatment for glaucoma.

As per the company’s website, its laser treatment utilizes a CO2 laser to thin the scleral tissue around Schlemm’s Canal without penetrating the scleral wall, thereby reducing IOP by facilitating adequate, functional percolation of intra-ocular fluid from the eye through the remaining membrane.  Percolation is achieved without penetrating the eye globe, thus reducing the likelihood of complications commonly experienced with trabeculectomy, which involves full thickness penetration.

Read the full release on Globes ^[1].